Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

NewAmsterdam Pharma (NAMS) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $222000.0 as the latest value for Q2 2024.

  • Quarterly Non-Current Deffered Revenue changed N/A to $222000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $222000.0 through Jun 2024, changed N/A year-over-year, with the annual reading at $1.0 million for FY2023, 78.74% down from the prior year.
  • Non-Current Deffered Revenue hit $222000.0 in Q2 2024 for NewAmsterdam Pharma, down from $444000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.6 million in Q4 2022 to a low of $222000.0 in Q2 2024.
  • Historically, Non-Current Deffered Revenue has averaged $1.6 million across 3 years, with a median of $731500.0 in 2023.
  • Biggest YoY gain for Non-Current Deffered Revenue was 77.77% in 2023; the steepest drop was 77.77% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $4.6 million in 2022, then tumbled by 77.77% to $1.0 million in 2023, then plummeted by 78.21% to $222000.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for NAMS at $222000.0 in Q2 2024, $444000.0 in Q1 2024, and $1.0 million in Q4 2023.